EMPA-REG OUTCOME: The Cardiologist's Point of View

被引：16

作者：

Pham, Son V. ^{[1
]}

Chilton, Robert J. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2017年 / 120卷 / 01期

关键词：

COTRANSPORTER; 2; INHIBITORS; TYPE-2; DIABETES-MELLITUS; HEART-RATE-VARIABILITY; CORONARY FLOW RESERVE; ARTERIAL STIFFNESS; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; VASCULAR-RESISTANCE; EMPAGLIFLOZIN; DISEASE;

D O I：

10.1016/j.amjcard.2017.05.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report. (C) 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：S53 / S58

页数：6

共 50 条

[41] Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME [J].

Pellicori, Pierpaolo ;

Ofstad, Anne Pernille ;

Fitchett, David ;

Zeller, Cordula ;

Wanner, Christoph ;

George, Jyothis ;

Zinman, Bernard ;

Brueckmann, Martina ;

Lindenfeld, JoAnn .

ESC HEART FAILURE, 2020, 7 (06) :3401-3407

[42] Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial [J].

Boehm, Michael ;

Slawik, Jonathan ;

Brueckmann, Martina ;

Mattheus, Michaela ;

George, Jyothis T. ;

Ofstad, Anne Pernille ;

Inzucchi, Silvio E. ;

Fitchett, David ;

Anker, Stefan D. ;

Marx, Nikolaus ;

Wanner, Christoph ;

Zinman, Bernard ;

Verma, Subodh .

EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (01) :126-135

[43] Implications of the EMPA-REG Trial for Clinical Care and Research [J].

Angeliki M. Stamatouli ;

Silvio E. Inzucchi .

Current Diabetes Reports, 2016, 16

[44] Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial [J].

Borg, Rikke ;

Persson, Frederik .

ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)

[45] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) [J].

Bernard Zinman ;

Silvio E Inzucchi ;

John M Lachin ;

Christoph Wanner ;

Roberto Ferrari ;

David Fitchett ;

Erich Bluhmki ;

Stefan Hantel ;

Joan Kempthorne-Rawson ;

Jennifer Newman ;

Odd Erik Johansen ;

Hans-Juergen Woerle ;

Uli C Broedl .

Cardiovascular Diabetology, 13

[46] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial [J].

Inzucchi, Silvio E. ;

Khunti, Kamlesh ;

Fitchett, David H. ;

Wanner, Christoph ;

Mattheus, Michaela ;

George, Jyothis T. ;

Ofstad, Anne Pernille ;

Zinman, Bernard .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09) :3025-3035

[47] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) [J].

Zinman, Bernard ;

Inzucchi, Silvio E. ;

Lachin, John M. ;

Wanner, Christoph ;

Ferrari, Roberto ;

Fitchett, David ;

Bluhmki, Erich ;

Hantel, Stefan ;

Kempthorne-Rawson, Joan ;

Newman, Jennifer ;

Johansen, Odd Erik ;

Woerle, Hans-Juergen ;

Broedl, Uli C. .

CARDIOVASCULAR DIABETOLOGY, 2014, 13

[48] Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians [J].

Naing, Soe ;

Poliyedath, Anupama ;

Khandelwal, Stutee ;

Sigala, Teresa .

POSTGRADUATE MEDICINE, 2016, 128 (08) :822-827

[49] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[50] Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? [J].

Coleman, Ruth L. ;

Gray, Alastair M. ;

Broedl, Uli C. ;

Fitchett, David ;

George, Jyothis T. ;

Woerle, Hans J. ;

Zinman, Bernard ;

Holman, Rury R. .

DIABETES OBESITY & METABOLISM, 2020, 22 (07) :1151-1156

← 1 2 3 4 5 →